Are you a US Healthcare Professional?

The content on this page is intended for US healthcare professionals only. By clicking "Yes," you confirm that you are a licensed healthcare professional in the United States.

To report an adverse event or for medical inquiries,
please contact CorMedix at medinfo@cormedix.com
  • Home >
  • Medical Affairs

Research Grants

CorMedix Therapeutics supports investigator-initiated research (IIR) and external research collaboration (ERC) that advances scientific knowledge and improves patient care in areas aligned with our therapeutic focus.

Investigator-Initiated Research (IIR)

Investigator-Initiated Research (IIRs) are clinical trials, registries, or other forms of research (e.g., real-world evidence studies, health outcomes research studies, or pre-clinical research) independently proposed and conducted by a third-party investigator, who assumes all responsibility for the study and serves as the regulatory sponsor-investigator.

External Research Collaborations (ERC)

External Research Collaborations (ERCs) are clinical trials, registries, or other forms of research (e.g., real-world evidence studies, health outcomes research studies, or pre-clinical research) where a third-party investigator independently proposes the study, or the Company solicits a research proposal from appropriate, qualified investigators. The investigator serves as the regulatory sponsor-investigator and assumes all responsibility for the conduct of the study. Medical personnel at the Company may collaborate scientifically with the investigator, including providing input on the study design, analyzing data and results, and authoring the study report or related publications.

For both IIRs and ERCs, the Company may provide drug, financial support, or both. These studies can involve investigational or marketed products.

CorMedix Therapeutics welcomes well-written, scientifically sound proposals that align with one of our research areas of interest.

Submit IIR/ERC Proposals:
Please use the form below to submit a research proposal. Ensure all pertinent information is included. Submit the completed form with supporting documents to iir@cormedix.com iir@cormedix.com.

Download

Strategic Areas of Interest

CorMedix Therapeutics welcomes research proposals in the following areas of medical and scientific interest:

DefenCath® (taurolidine and heparin) AOI
  • Real-world use of DefenCath in:
    • Home hemodialysis
    • Acute kidney injury
  • Preclinical or clinical studies on DefenCath in:
    • Catheter salvage
    • Peritoneal dialysis
  • Qualitative and/or mixed methodology research on the topic of CLABSI prevention and/or management from diverse viewpoints including, but not limited to:
    • Patients
    • Caregivers
    • Healthcare professionals
REZZAYO® (rezafungin for injection) AOI

Patient-Centered Research in Long-Term Antifungal (AF) Treatment on Patient Quality of Life

  • Evaluate the impact of once weekly antifungal therapy on patient Quality of life (QoL) in the outpatient setting
    • Patient preferences and awareness of treatment options
    • Compliance with monitoring requirements and adherence challenges with daily AF treatment

Real-World Evidence (RWE) on Rezafungin

  • Assess the clinical and economic outcomes associated with the use of rezafungin in Transition of Care protocols
  • Evaluate the efficacy of rezafungin in patients with candidemia or invasive candidiasis caused by strains resistant to other echinocandins
  • Compare clinical and microbiological outcomes with rezafungin compared to other echinocandins for the treatment of candidemia or invasive candidiasis caused by Candida glabrata
  • Characterize the pharmacokinetics and pharmacodynamics (PK/PD) of rezafungin in real-world clinical practice, including the use of alternative dosing strategies and therapeutic drug monitoring.
  • Evaluate the utilization of rezafungin, including but not limited to:
    • Management of deep-seated infections
    • Utilization as chronic suppressive therapy
    • Outpatient treatment of mucocutaneous candidiasis, including vulvovaginal candidiasis, esophageal candidiasis, and STAT1 GOF associated infections
    • Management of prosthetic and orthopedic surgery-related infections
    • Treatment of infection caused by Candida auris
    • Initiation of rezafungin earlier than day of hospital discharge
  • Assess the efficacy of rezafungin as initial or salvage therapy for invasive infections caused by Aspergillus spp.
  • Assess the efficacy of rezafungin for fungal infections beyond Candida and Aspergillus spp.

Addressing Unmet Needs in Antifungal Prophylaxis

  • Evaluate the efficacy of rezafungin to prevent IFD in patient populations beyond HSCT

Strategic areas of interest are reviewed periodically and may be updated. Please contact iir@cormedix.com with questions about alignment of your research proposal.